1.Clinical factors associated with composition of lung microbiota and important taxa predicting clinical prognosis in patients with severe community-acquired pneumonia.
Sisi DU ; Xiaojing WU ; Binbin LI ; Yimin WANG ; Lianhan SHANG ; Xu HUANG ; Yudi XIA ; Donghao YU ; Naicong LU ; Zhibo LIU ; Chunlei WANG ; Xinmeng LIU ; Zhujia XIONG ; Xiaohui ZOU ; Binghuai LU ; Yingmei LIU ; Qingyuan ZHAN ; Bin CAO
Frontiers of Medicine 2022;16(3):389-402
Few studies have described the key features and prognostic roles of lung microbiota in patients with severe community-acquired pneumonia (SCAP). We prospectively enrolled consecutive SCAP patients admitted to ICU. Bronchoscopy was performed at bedside within 48 h of ICU admission, and 16S rRNA gene sequencing was applied to the collected bronchoalveolar lavage fluid. The primary outcome was clinical improvements defined as a decrease of 2 categories and above on a 7-category ordinal scale within 14 days following bronchoscopy. Sixty-seven patients were included. Multivariable permutational multivariate analysis of variance found that positive bacteria lab test results had the strongest independent association with lung microbiota (R2 = 0.033; P = 0.018), followed by acute kidney injury (AKI; R2 = 0.032; P = 0.011) and plasma MIP-1β level (R2 = 0.027; P = 0.044). Random forest identified that the families Prevotellaceae, Moraxellaceae, and Staphylococcaceae were the biomarkers related to the positive bacteria lab test results. Multivariable Cox regression showed that the increase in α-diversity and the abundance of the families Prevotellaceae and Actinomycetaceae were associated with clinical improvements. The positive bacteria lab test results, AKI, and plasma MIP-1β level were associated with patients' lung microbiota composition on ICU admission. The families Prevotellaceae and Actinomycetaceae on admission predicted clinical improvements.
Acute Kidney Injury/complications*
;
Bacteria/classification*
;
Chemokine CCL4/blood*
;
Community-Acquired Infections/microbiology*
;
Humans
;
Lung
;
Microbiota/genetics*
;
Pneumonia, Bacterial/diagnosis*
;
Prognosis
;
RNA, Ribosomal, 16S/genetics*
2.Serum Vascular Endothelial Growth Factor in Pediatric Patients with Community-Acquired Pneumonia and Pleural Effusion.
Seong Hwan CHOI ; Eun Young PARK ; Hye Lim JUNG ; Jae Won SHIM ; Deok Soo KIM ; Moon Soo PARK ; Jung Yeon SHIM
Journal of Korean Medical Science 2006;21(4):608-613
This study investigated the serum vascular endothelial growth factor (VEGF) levels in children with community-acquired pneumonia. Serum VEGF levels were measured in patients with pneumonia (n=29) and in control subjects (n=27) by a sandwich enzyme-linked immunosorbent assay. The pneumonia group was classified into bronchopneumonia with pleural effusion (n=1), bronchopneumonia without pleural effusion (n=15), lobar pneumonia with pleural effusion (n=4), and lobar pneumonia without pleural effusion (n=9) groups based on the findings of chest radiographs. We also measured serum IL-6 levels and the other acute inflammatory parameters. Serum levels of VEGF in children with pneumonia were significantly higher than those in control subjects (p<0.01). Children with lobar pneumonia with or without effusion showed significantly higher levels of serum VEGF than children with bronchopneumonia. For lobar pneumonia, children with pleural effusion showed higher levels of VEGF than those without pleural effusion. Children with a positive urinary S. pneumonia antigen test also showed higher levels of VEGF than those with a negative result. Serum IL-6 levels did not show significant differences between children with pneumonia and control subjects. Serum levels of VEGF showed a positive correlation with the erythrocyte sedimentation rate in the children with pneumonia. In conclusion, VEGF may be one of the key mediators that lead to lobar pneumonia and parapneumonic effusion.
Vascular Endothelial Growth Factor A/*blood
;
Streptococcus pneumoniae/growth & development/immunology
;
Pneumonia, Bacterial/*blood/complications/microbiology
;
Pleural Effusion/*blood/complications/microbiology
;
Mycoplasma pneumoniae/growth & development/immunology
;
Male
;
Interleukin-6/blood
;
Infant
;
Humans
;
Female
;
Enzyme-Linked Immunosorbent Assay
;
Community-Acquired Infections/blood/microbiology
;
Child, Preschool
;
Child
;
Antigens, Bacterial/immunology
;
Antibodies, Bacterial/immunology
;
Adolescent
3.Atypical Pathogens as Etiologic Agents in Hospitalized Patients with Community-Acquired Pneumonia in Korea: A Prospective Multi-Center Study.
Jang Wook SOHN ; Seung Chul PARK ; Young Hwa CHOI ; Heung Jeong WOO ; Yong Kyun CHO ; Jin Soo LEE ; Hee Sun SIM ; Min Ja KIM
Journal of Korean Medical Science 2006;21(4):602-607
Local epidemiologic data on the etiologies of patients hospitalized with community-acquired pneumonia (CAP) is needed to develop guidelines for clinical practice. This study was conducted prospectively to determine the proportion of atypical bacterial pathogens in adults patients hospitalized with CAP in Korea between October 2001 and December 2002. Microbiological diagnosis was determined by serology for antibodies to Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneu-mophila. Nucleic acid of M. pneumoniae and C. pneumoniae in respiratory samples and Legionella antigen in urine samples were detected. The study population consisted of 126 patients (71 males, 55 females), averaging 54.6 yr (SD+/-17.8), whose paired sera were available. An etiologic diagnosis for atypical pathogens was made in 18 patients (14.3%): C. pneumoniae 9 (7.1%), M. pneumoniae 8 (6.3%), and L. pneumophila 3 patients (2.4%). Streptococcus preumoniae and other typical pathogens were isolated from 36 patients (28.6%). Of 126 patients, 16 (12.7%) were admitted to intensive care unit and atypical pathogens were identified in 5 patients (31.3%). Initial clinical features of patients with pneumonia due to atypical, typical or undetermined pathogens were indistinguishable. We conclude that atypical pathogens should be seriously considered in hospitalized patients with CAP, when initiating empiric treatment in Korea.
RNA, Ribosomal, 16S/genetics
;
Prospective Studies
;
Polymerase Chain Reaction
;
Pneumonia, Bacterial/blood/*microbiology/urine
;
Mycoplasma pneumoniae/genetics/immunology/*isolation & purification
;
Middle Aged
;
Male
;
Legionella pneumophila/genetics/immunology/*isolation & purification
;
Korea
;
Humans
;
Hospitalization/statistics & numerical data
;
Female
;
Community-Acquired Infections/microbiology
;
Chlamydophila pneumoniae/genetics/immunology/*isolation & purification
;
Antigens, Bacterial/urine
;
Antibodies, Bacterial/blood
;
Aged
;
Adult